These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 7637143)

  • 21. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
    Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
    BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
    Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
    Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PSA and the conservative treatment of early prostate cancer.
    Albertsen PC
    Arch Ital Urol Androl; 2006 Dec; 78(4):152-3. PubMed ID: 17269621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.
    Aizer AA; Chen MH; Hattangadi J; D'Amico AV
    BJU Int; 2014 Jan; 113(1):43-50. PubMed ID: 23473327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
    Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
    Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advancing age within established Gleason score categories and the risk of prostate cancer-specific mortality (PCSM).
    Russo AL; Chen MH; Aizer AA; Hattangadi JA; D'Amico AV
    BJU Int; 2012 Oct; 110(7):973-9. PubMed ID: 22954029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Variation in treatment associated with life expectancy in a population-based cohort of men with early-stage prostate cancer.
    Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
    Cancer; 2014 Dec; 120(23):3642-50. PubMed ID: 25042117
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC; Roemeling S; Roobol MJ; Aus G; Hugosson J; Rannikko AS; Tammela TL; Bangma CH; Schröder FH
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy.
    Miyamoto S; Ito K; Miyakubo M; Suzuki R; Yamamoto T; Suzuki K; Suzuki K; Yamanaka H
    Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):75-86. PubMed ID: 21986985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
    Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
    Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Should we treat localized prostate cancer? An opinion.
    Menon M; Parulkar BG; Baker S
    Urology; 1995 Nov; 46(5):607-16. PubMed ID: 7495109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer.
    Bratt O; Folkvaljon Y; Hjälm Eriksson M; Akre O; Carlsson S; Drevin L; Franck Lissbrant I; Makarov D; Loeb S; Stattin P
    Eur Urol; 2015 Jul; 68(1):53-8. PubMed ID: 25813688
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer.
    Mullins JK; Han M; Pierorazio PM; Partin AW; Carter HB
    J Urol; 2012 May; 187(5):1620-5. PubMed ID: 22425079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    D'Amico AV; Renshaw AA; Sussman B; Chen MH
    JAMA; 2005 Jul; 294(4):440-7. PubMed ID: 16046650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Continued undertreatment of older men with localized prostate cancer.
    Schwartz KL; Alibhai SM; Tomlinson G; Naglie G; Krahn MD
    Urology; 2003 Nov; 62(5):860-5. PubMed ID: 14624909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health outcomes in older men with localized prostate cancer: results from the Prostate Cancer Outcomes Study.
    Hoffman RM; Barry MJ; Stanford JL; Hamilton AS; Hunt WC; Collins MM
    Am J Med; 2006 May; 119(5):418-25. PubMed ID: 16651054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Causes of mortality after dose-escalated radiation therapy and androgen deprivation for high-risk prostate cancer.
    Tendulkar RD; Hunter GK; Reddy CA; Stephans KL; Ciezki JP; Abdel-Wahab M; Stephenson AJ; Klein EA; Mahadevan A; Kupelian PA
    Int J Radiat Oncol Biol Phys; 2013 Sep; 87(1):94-9. PubMed ID: 23920389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.